Compare Illumina, Inc. (ILMN) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Norwegian Cruise Line Holdings Ltd — how do they compare? Illumina, Inc. trades at $192.36 (market cap $27.94B), while Norwegian Cruise Line Holdings Ltd trades at $19.48 (market cap $8.95B). The key difference: Illumina, Inc. is far larger — about 3.1× Norwegian Cruise Line Holdings Ltd's market cap, and Illumina, Inc. is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| ILMN | NCLH | |
|---|---|---|
Market Cap | $27.94B | $8.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $194.33 | $26.94 |
52-Week Low | $91.00 | $14.79 |
Enterprise Value | $29.33B | $23.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $192.53, up 3.15% today, with bullish technical signals and strong fundamental recovery. The stock shows robust profitability with a 19.42% net margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and new executive appointments, reinforcing growth prospects in genomics.
Outlook remains positive driven by sequencing demand and cost control, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is Buy with a $178 target, though the current price exceeds this, suggesting cautious optimism amid execution risks.
NCLH trades at $19.45, down slightly by 0.05%, with a neutral technical signal and bearish moving averages. The company reported revenue of $9.83B in 2025, with net income of $423.25M and a profit margin of 4.3%. Recent quarters show consistent earnings beats, including Q1 2026 EPS of $0.23 versus $0.15 expected. Analyst consensus is bullish with a $20.82 price target, and cash flow trends improved to a positive net of $19M in 2025.
The outlook for NCLH is cautiously optimistic, supported by earnings momentum and analyst buy ratings, but risks include high debt levels and macroeconomic sensitivity. Investment opportunity lies in continued operational recovery and potential upside to price targets, while volatility from fuel costs and travel demand poses challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
